Salbutamol, Pharmacogenetics and Breathing Mechanics
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Athletes using asthma medications called β2-agonists win a disproportionately high number of
medals at Olympic Games. Due to a large variety in the genes that affect how individuals
respond to β2-agonists, the investigators will look at variations in the genetic response to
these medications by dividing athletes into high-responders and low-responders. The
investigators will then compare athletic performance after the inhalation of β2-agonists to
placebo. Furthermore, the investigators will analyze the effect of β2-agonists on breathing
mechanics. Due to differences in their anatomy females may decrease the energy needed for
breathing during high-intensity exercise to a greater extent compared to male athletes after
the inhalation of β2-agonists.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Collaborators:
World Anti-doping Agency World Anti-Doping Agency (WADA)